A subscription weight-loss program built around compounded tirzepatide, the dual GIP/GLP-1 drug also sold as Zepbound and Mounjaro. Each 30-day supply ships with refills, plus a structured layer most telehealth rivals skip: an online weight-loss course, an e-book, customized meal plans, and monthly physician reviews with dose adjustments. It suits people who want medication plus coaching and accountability rather than a bare vial. The trade-off is a locked-in monthly refill cycle and no brand-name product; the program's own materials claim most patients lose at least 10% of body weight, with many above 20%, which tracks published tirzepatide trial results.
In stockReturn policy
Rated 4.9 out of 5 across 70 ratings, buyers describe meaningful appetite suppression and steady weight loss, and value the meal plans and responsive support. Complaints center on gastrointestinal side effects and the commitment of the recurring refill schedule.
The Healthogenics Tirzepatide Weight Loss Program combines tirzepatide, a GLP-1 agonist medication, with a custom program on lifestyle changes. The medication suppresses appetite and food cravings and increases the feeling of fullness. It slows stomach emptying and helps stimulate the pancreas to increase insulin production.
The program is meant to lower weight, waist size, blood pressure, blood sugar and inflammation. The majority of patients experience at least a 10% weight loss, and many lose more than 20%. It is a medically assisted approach that does not involve surgery or stimulants.
A physician reviews each patient's medical intake form before treatment. The medication is not prescribed to everyone, and a Healthogenics medical professional should be consulted before starting.